国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2010年
4期
239-241
,共3页
肝炎,乙型,慢性%拉米夫定%干扰素%抗病毒治疗
肝炎,乙型,慢性%拉米伕定%榦擾素%抗病毒治療
간염,을형,만성%랍미부정%간우소%항병독치료
Hepatitis B,chronic%Lamivudine%Interferons%Antiviral therapy
目的 探讨拉米夫定治疗慢性乙型肝炎出现耐药后改用IFN-α抗病毒的疗效.方法 将42例经拉米夫定治疗后耐药的患者分为治疗组和对照组进行观察.治疗组24例改用IFN-α抗病毒治疗,对照组18例未用其他抗病毒药,定期检查ALT、HBV DNA和HBeAg/抗-HBe.结果 治疗组ALT复常率为87.5%,与对照组的55.6%比较,差异有统计学意义(χ2=5.430,P＜0.05).治疗组中有5例患者HBV DNA阴转,6例患者HBeAg/抗-HBe血清转换,均明显高于对照组,差异有统计学意义(χ2=4.257,P＜0.05;χ2=5.250,P＜0.05).结论 拉米夫定治疗慢性乙型肝炎出现耐药后改用IFN-α的抗病毒治疗是有效的.
目的 探討拉米伕定治療慢性乙型肝炎齣現耐藥後改用IFN-α抗病毒的療效.方法 將42例經拉米伕定治療後耐藥的患者分為治療組和對照組進行觀察.治療組24例改用IFN-α抗病毒治療,對照組18例未用其他抗病毒藥,定期檢查ALT、HBV DNA和HBeAg/抗-HBe.結果 治療組ALT複常率為87.5%,與對照組的55.6%比較,差異有統計學意義(χ2=5.430,P＜0.05).治療組中有5例患者HBV DNA陰轉,6例患者HBeAg/抗-HBe血清轉換,均明顯高于對照組,差異有統計學意義(χ2=4.257,P＜0.05;χ2=5.250,P＜0.05).結論 拉米伕定治療慢性乙型肝炎齣現耐藥後改用IFN-α的抗病毒治療是有效的.
목적 탐토랍미부정치료만성을형간염출현내약후개용IFN-α항병독적료효.방법 장42례경랍미부정치료후내약적환자분위치료조화대조조진행관찰.치료조24례개용IFN-α항병독치료,대조조18례미용기타항병독약,정기검사ALT、HBV DNA화HBeAg/항-HBe.결과 치료조ALT복상솔위87.5%,여대조조적55.6%비교,차이유통계학의의(χ2=5.430,P＜0.05).치료조중유5례환자HBV DNA음전,6례환자HBeAg/항-HBe혈청전환,균명현고우대조조,차이유통계학의의(χ2=4.257,P＜0.05;χ2=5.250,P＜0.05).결론 랍미부정치료만성을형간염출현내약후개용IFN-α적항병독치료시유효적.
Objective To evaluate the efficacy of interferon-α in the treatment of chronic hepatitis B patients following lamivudine resistance. Methods 42 patients with lamivudine resistance were enrolled and randomized into treatment group and control group. In treatment group, patients ( n = 24) received IFN-α; in control group ( n = 18),lamivudine was directly discontinued and no antiviral agent were given. Liver function tests and serum virologic responses were evaluated at regular interval in all patients. Results There were statistical differences between the treatment group (87.5%) and control group (55.6%) in normalization rate of ALT (χ2 = 5.430, P ＜ 0.05). In treatment group, 5cases became negative in HBV DNA, and 6 cases had HBeAg/anti-HBe seroconversion, and the both were significantly higher than those in control group( χ2 = 4.257, P ＜ 0.05; χ2 = 5.250, P ＜ 0.05). Conclusions The study shows that IFN-α in the treatment of chronic hepatitis B patients following lamivudine resistance is beneficial.
